Atara Biotherapeutics, Inc. (ATRA) Cash Flow Statement
Where ATRA’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$50.9M
- Capital expenditures
- $0 0.0% of revenue
- Free cash flow
- −$50.9M −42.2% margin
- Returned to shareholders
- —
- Change in cash
- −$16.7M cash at year-end $8.5M
Cash from operations
−$50.9M
Investments (net)
+$17.2M
Acquisitions & other
+$948,000
Net borrowing (repayment)
−$250,000
Shares issued
+$16.3M
Change in cash
−$16.7M
Drawn to scale: where the cash came from and how it was used. Hover for values.
ATRA operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
ATRA cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$60.0M2016 | −$50.9M2025 | — | |
| Capital expenditures | $3.0M2016 | $02025 | −100.0% | |
| Free cash flow | −$63.0M2016 | −$50.9M2025 | — | |
| Free cash flow margin | −5,216.0%2020 | −42.2%2025 | +5,173.8 pts | |
| Stock-based compensation | $16.8M2016 | $9.8M2025 | −5.9%/yr | |
| Dividends paid | $02016 | $623,0002022 | — | |
| Share buybacks (net) | $94,0002016 | $94,0002023 | 0.0%/yr | |
| Capex / revenue | 127.1%2020 | 0.0%2025 | −127.1 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
ATRA cash flow by activity
OperatingInvestingFinancingChange in cash
ATRA net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
ATRA cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | $32.7M | −$85.4M | −$276.1M | −$228.3M | −$340.1M | −$306.6M | −$291.0M | −$230.7M | −$119.5M | −$79.0M |
| Depreciation & amortization | $2.1M | $5.1M | $4.8M | $5.7M | $9.3M | $8.3M | $7.1M | $3.7M | $956,000 | $383,000 |
| Stock-based compensation | $9.8M | $27.0M | $45.4M | $53.8M | $53.9M | $51.4M | $51.7M | $33.8M | $23.1M | $16.8M |
| Change in working capital | −$104.7M | −$31.0M | $15.3M | −$61.5M | $52.6M | $63.7M | −$4.1M | $15.0M | $7.2M | −$725,000 |
| Other non-cash items | $9.2M | $15.6M | $17.6M | −$40.2M | $3.8M | $2.5M | $732,000 | −$1.6M | $732,000 | $2.6M |
| Cash from operating activities | −$50.9M | −$68.7M | −$193.0M | −$270.4M | −$220.5M | −$180.8M | −$235.6M | −$179.8M | −$87.5M | −$60.0M |
| Investing activities | ||||||||||
| Capital expenditures | $0 | −$246,000 | −$1.2M | −$4.2M | −$10.6M | −$4.5M | −$5.7M | −$35.9M | −$20.2M | −$3.0M |
| Investments (net) | $17.2M | $8.6M | $165.1M | $112.4M | $32.8M | −$116.2M | $66.0M | −$160.4M | $120.1M | $86.8M |
| Acquisitions & other investing | $948,000 | $246,000 | −$40.1M | $94.8M | $0 | $0 | $161,000 | $0 | −$1.2M | $0 |
| Cash from investing activities | $18.1M | $8.6M | $123.9M | $203.0M | $22.3M | −$120.7M | $60.5M | −$196.3M | $98.7M | $83.7M |
| Financing activities | ||||||||||
| Dividends paid | — | — | — | −$623,000 | −$1.2M | −$1.5M | −$6.7M | — | $0 | $0 |
| Share repurchases & issuance (net) | — | — | −$94,000 | −$623,000 | −$1.2M | −$1.5M | −$6.7M | −$7.5M | −$357,000 | −$94,000 |
| Net borrowing (repayment) | −$250,000 | −$892,000 | −$947,000 | $30.1M | −$254,000 | −$389,000 | −$486,000 | −$528,000 | $9.9M | −$528,000 |
| Shares issued | $16.3M | $60.0M | $32.6M | $52.5M | $98.7M | $423.0M | $188.6M | $340.9M | $0 | $0 |
| Other financing | $34,000 | $223,000 | −$29.5M | −$28.3M | $8.0M | $8.0M | $14.0M | $24.7M | $10.5M | $1.1M |
| Cash from financing activities | $16.1M | $59.3M | $2.0M | $53.1M | $103.9M | $427.6M | $188.8M | $357.5M | $20.0M | $506,000 |
| Summary | ||||||||||
| Net change in cash | −$16.7M | −$811,000 | −$67.1M | −$14.4M | −$94.3M | $126.1M | $13.6M | −$18.5M | $31.3M | $24.2M |
| Cash at end of period | $8.5M | $25.2M | $26.0M | $93.1M | $107.5M | $201.8M | $75.7M | $62.1M | $79.2M | $48.0M |
| Free cash flow | −$50.9M | −$69.0M | −$194.2M | −$274.6M | −$231.1M | −$185.3M | −$241.4M | −$215.7M | −$107.7M | −$63.0M |
| Free cash flow margin | −42.2% | −53.5% | −2,265.3% | −432.0% | −1,136.2% | −5,216.0% | — | — | — | — |
| Capex / revenue | 0.0% | 0.2% | 14.3% | 6.6% | 52.0% | 127.1% | — | — | — | — |
| Operating cash flow / net income | −1.56 | — | — | — | — | — | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$4.8M | −$4.1M | −$3.4M | −$4.3M | $2.4M | $38.0M | −$12.7M | −$21.9M | −$19.0M | −$31.8M | −$60.5M | −$69.8M |
| Depreciation & amortization | $14,000 | $29,000 | $49,000 | $36,000 | $236,000 | $1.8M | $1.1M | $1.2M | $1.3M | $1.4M | $1.2M | $1.2M |
| Stock-based compensation | $394,000 | $749,000 | $1.5M | $1.2M | $2.8M | $4.2M | $5.8M | $6.4M | $6.3M | $8.4M | $9.9M | $11.1M |
| Change in working capital | $702,000 | −$754,000 | −$2.0M | −$7.9M | −$12.8M | −$82.1M | −$22.4M | $6.6M | −$3.4M | −$11.7M | −$7.3M | $2.0M |
| Other non-cash items | $386,000 | $1.0M | −$1.9M | $1.1M | $29,000 | $10.0M | $3.7M | $3.7M | $4.1M | $4.1M | $6.2M | $4.1M |
| Cash from operating activities | −$3.3M | −$3.1M | −$5.7M | −$9.8M | −$7.3M | −$28.1M | −$24.5M | −$4.0M | −$10.6M | −$29.6M | −$50.4M | −$51.3M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $0 | −$90,000 | $0 | −$29,000 | −$127,000 | −$44,000 | −$281,000 |
| Investments (net) | −$6.6M | $0 | $7.9M | −$2.4M | −$5.1M | $17.2M | $3.4M | −$16.7M | $7.2M | $14.7M | $9.9M | $70.4M |
| Acquisitions & other investing | $0 | — | $555,000 | $0 | $0 | $0 | $90,000 | $0 | $29,000 | $127,000 | $44,000 | $281,000 |
| Cash from investing activities | −$6.6M | — | $8.4M | −$2.4M | −$5.1M | $17.2M | $3.4M | −$16.7M | $7.2M | $14.7M | $9.9M | $70.4M |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | — | — | — | — | — | — | −$6,000 | $6,000 | — | −$6,000 | $94,000 | — |
| Net borrowing (repayment) | $0 | $0 | $0 | $0 | $0 | −$250,000 | −$235,000 | −$197,000 | — | — | — | — |
| Shares issued | $4.8M | $3.0M | $0 | $1.0M | $15.3M | $0 | $0 | $36.0M | $0 | $24.4M | $1.5M | $0 |
| Other financing | $0 | $0 | −$3,000 | $11,999 | $0 | $0 | −$87,000 | −$6,000 | −$324,000 | −$227,000 | −$128,000 | −$208,000 |
| Cash from financing activities | $4.8M | $3.0M | −$3,000 | $1.0M | $15.3M | −$250,000 | −$328,000 | $35.8M | −$324,000 | $24.1M | $1.5M | −$208,000 |
| Summary | ||||||||||||
| Net change in cash | −$5.1M | −$122,000 | $2.7M | −$11.2M | $2.9M | −$11.2M | −$21.4M | $15.1M | −$3.8M | $9.2M | −$39.0M | $18.9M |
| Cash at end of period | $3.2M | $8.4M | $8.5M | $5.7M | $16.9M | $14.0M | $25.2M | $46.6M | $31.5M | $35.2M | $26.0M | $64.9M |
| Free cash flow | −$3.3M | −$3.1M | −$5.7M | −$9.8M | −$7.3M | −$28.1M | −$24.6M | −$4.0M | −$10.7M | −$29.7M | −$50.5M | −$51.6M |
| Free cash flow margin | −529.8% | −595.5% | −357.2% | −283.4% | −41.6% | −28.7% | −75.0% | −9.9% | −37.3% | −108.7% | −1,186.5% | −2,414.7% |
| Capex / revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 0.1% | 0.5% | 1.0% | 13.1% |
| Operating cash flow / net income | — | — | — | — | −3.07 | −0.74 | — | — | — | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
ATRA cash generation
In fiscal 2025 (ended December 31, 2025), Atara Biotherapeutics generated -$50.9 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$50.9 million, −42.2% of revenue. Cash and equivalents fell by $16.7 million over the year.
Related: ATRA income statement, ATRA balance sheet. See the ATRA stock overview for the latest quote and news.
ATRA cash flow FAQ
What is Atara Biotherapeutics's free cash flow?
Atara Biotherapeutics's free cash flow was -$50.9 million in fiscal 2025: -$50.9 million of operating cash flow minus $0 of capital expenditures It was -$69.0 million a year earlier..
How much cash does Atara Biotherapeutics generate from operations?
Atara Biotherapeutics generated -$50.9 million of cash from operating activities in fiscal 2025, −1.56 times its net income of $32.7 million.